Hepato-gastroenterology · 2004
Ceftriaxone is twice as cost-effective as standard therapy in biliary tract infection.
Клиническое исследованиеКонтролируемое клиническое исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zoepf Thomas, Jakobs Ralf, Riemann Juergen F
Аннотация
BACKGROUND/AIMS: Various antibiotics, mainly cephalosporins and broad-spectrum penicillins, are indicated in biliary tract infection. The primary endpoint was to compare the cost-effectiveness of ceftriaxone (Rocephin) 1 g once daily vs. standard therapy two or three times daily.
METHODOLOGY: A prospective multicenter observational study, matched-pair analysis of 902 patients receiving ceftriaxone or standard therapy (second-generation cephalosporin, broad-spectrum penicillin or a combination of aminopenicillin and beta-lactamase inhibitor) in 75 hospitals yielded 173 pairs matched for definite risk criteria. Both groups received comparable accompanying endoscopic antiobstructive treatment. Cost parameters included primary antibiotic purchase, total antibiotic purchase (including combination and second-line drugs), and infusion preparation and administration.
RESULTS: 87.9% of patients in the ceftriaxone group vs. 73.4% in the standard group received antibacterial monotherapy, for 7.5 vs. 9.1 days respectively (p=0.001). Therapy was equally effective in both groups. Overall treatment costs, including antibiotic purchase and infusion preparation/administration, were 170.84 vs. 320.46, respectively (p=0.0001).
CONCLUSIONS: Ceftriaxone 1 g once daily is approximately twice as cost-effective as standard therapy in biliary tract infection: lower concomitant medication costs, a shorter treatment course, and lower antibiotic administration costs achieved an approximate 50% saving.
METHODOLOGY: A prospective multicenter observational study, matched-pair analysis of 902 patients receiving ceftriaxone or standard therapy (second-generation cephalosporin, broad-spectrum penicillin or a combination of aminopenicillin and beta-lactamase inhibitor) in 75 hospitals yielded 173 pairs matched for definite risk criteria. Both groups received comparable accompanying endoscopic antiobstructive treatment. Cost parameters included primary antibiotic purchase, total antibiotic purchase (including combination and second-line drugs), and infusion preparation and administration.
RESULTS: 87.9% of patients in the ceftriaxone group vs. 73.4% in the standard group received antibacterial monotherapy, for 7.5 vs. 9.1 days respectively (p=0.001). Therapy was equally effective in both groups. Overall treatment costs, including antibiotic purchase and infusion preparation/administration, were 170.84 vs. 320.46, respectively (p=0.0001).
CONCLUSIONS: Ceftriaxone 1 g once daily is approximately twice as cost-effective as standard therapy in biliary tract infection: lower concomitant medication costs, a shorter treatment course, and lower antibiotic administration costs achieved an approximate 50% saving.